


Healthcare Industry News: IIb/IIIa
News Release - June 21, 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Source: Cardiome Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
